Journal of Advanced Medicine (JAM)

REVIEW

AI-Driven Genomics Architectures Applications And The Transition To Self Driving Biomedical Systems

Babajan Banaganapalli [1,*]

[1] Department of Genetic Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

Abstract: The integration of Artificial Intelligence (AI) into the field of genomics represents a paradigm shift that is redefining the boundaries of biological research and clinical medicine. As high-throughput sequencing technologies generate petabytes of high-dimensional data, traditional statistical frameworks have reached their analytical limits. This systematic review examines the current state and projected trajectory of AI-driven genomics, focusing on the transition from classical machine learning to deep learning, transformer-based architectures, and generative AI. We provide a comprehensive analysis of AI's impact on variant calling, genome annotation, functional genomics, and multi-omics integration. Key findings indicate that AI models such as DeepVariant and AlphaFold2 have achieved near-human or supra-human accuracy in identifying genetic variants and predicting protein structures, respectively. Furthermore, the emergence of "Self-Driving Laboratories" and "Digital Twins" suggests a future where experimental biology is largely autonomous and predictive. However, significant challenges remain, including the persistent bias in datasets dominated by European ancestries, the "black box" nature of deep neural networks, and the complex ethical implications of prenatal and pediatric genomic AI. This report synthesizes 195 studies to outline a roadmap for 2026–2035, emphasizing the need for transparent, explainable, and equitable AI frameworks. By 2032, the goal is to provide timely genomic sequencing access to all 194 WHO Member States, powered by decentralized, real-time AI surveillance.

Keywords: Artificial Intelligence, Genomic, DeepVariant, Biomedical Systems.

Submitted: December 01, 2025
Accepted: March 01, 2026
Published: March 07, 2026

Vol. 2, **No.** 1, 2026, 29-37.

***Corresponding author:**
✉ Babajan Banaganapalli
bbabajan@kau.edu.sa

1 The Evolution Of Computational Genomics And The Shift Toward Cognitive Automation

The history of genomics is inextricably linked to the progression of computing. From the initial automated blood analyzers of the 1950s to the specialized bioinformatics tools of the 1980s, the field has continuously sought to automate the labor-intensive tasks of molecular analysis.1 In the contemporary era, the widespread adoption of high-throughput sequencing (HTS) has led to an exponential growth of biological data, necessitating tools that do not merely execute pre-programmed steps but possess the capacity for "cognitive automation".1 While traditional statistical techniques and early machine learning methods like decision trees and support vector machines (SVMs) were effective for well-defined problems, they frequently struggled with the complex, non-linear dependencies inherent in high-dimensional genomic data.3

The transition from traditional machine learning (ML) to deep learning (DL) marked the beginning of a new analytical epoch. Traditional ML often required manual feature extraction, a process that was both time-consuming and limited by human understanding of biological motifs.4 In contrast, deep learning architectures particularly neural networks enable models to learn directly from raw data, automatically discovering hierarchies of features and patterns that define gene regulation and disease pathogenicity.4 This shift has enabled researchers to move from descriptive analyses toward predictive, mechanistic frameworks that can simulate biological systems under various conditions.8

Today, AI and genomics operate within a dynamic feedback loop. AI enhances genomic research by streamlining experimental design, automating laboratory procedures, and facilitating the analysis of multi-layered biological information, while the resulting data provide the training signals needed

to refine even more sophisticated models.6 This convergence is the cornerstone of modern precision medicine, where treatments are tailored to the unique molecular portrait of an individual patient rather than the "average" case.10 (Figure 1).

2 Core Ai Architectures And Learning Paradigms In Genomic Research

The efficacy of AI in genomics is largely dictated by the underlying neural architecture and the learning paradigm employed. Each architecture is suited to specific data modalities, from the sequential nature of DNA to the spatial characteristics of medical imaging.

3 Deep Learning And Sequential Modeling

Convolutional Neural Networks (CNNs), which were originally designed for image processing, have found unexpected utility in genomics.3 By representing aligned sequencing reads as image-like tensors, models can detect subtle patterns of genetic variation with higher sensitivity than traditional probabilistic methods.12 This methodology is central to the DeepVariant pipeline, which uses an Inception-v3 architecture to distinguish between true variants and sequencing artifacts.12

For sequential data, Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) networks were initially favored due to their ability to process information over time.3 These models have been instrumental in tracking biomarker levels over time, such as monitoring circulating tumor DNA (ctDNA) during cancer treatment.15 However, RNNs face significant challenges with long-range dependencies where information at one end of a genomic sequence influences a functional element far downstream.3 This limitation led to the rise of transformer-based architectures.

4 The Transformer Revolution And Generative Ai

Transformers have revolutionized Natural Language Processing (NLP) and are now doing the same for the "language" of life.3 Utilizing an attention mechanism, Transformers can evaluate the importance of different parts of a sequence simultaneously, making them exceptionally adept at capturing long-range interactions in the genome.7 Large Language Models (LLMs), based on these architectures, have shown remarkable capability in interpreting unstructured medical data, mapping clinical phenotypes to the Human Phenotype Ontology (HPO), and even "writing" novel genomic sequences with specific functional properties.3

Generative AI takes this a step further by moving beyond inference to simulation and design. These models can replicate functional genomes, optimize genome editing protocols such as CRISPR-Cas9, and generate synthetic training data to bolster models for rare diseases where real-world data is sparse.2 The introduction of generative AI into genomics allows for the simulation of genotype-environment-phenotype relationships, providing a predictive lens that was previously unimaginable.7

5 Ai Driven Variant Calling And Genome Annotation

Variant calling is the foundational process of identifying differences between a patient's DNA and a reference sequence. It is a multi-step process involving sequencing, mapping, and refinement.12 AI has transformed this domain by replacing traditional statistical filters with deep learning models that can handle the noise and complexity of high-throughput data.12

6 Benchmarking The New Generation Of Callers

Current AI-based variant callers represent a cutting-edge approach that significantly reduces false-positive and false-negative rates.12 DeepVariant, developed by Google Health, is an open-source tool that uses CNNs to analyze pileup images of aligned reads.12 It has achieved F1 scores for single nucleotide variants (SNVs) as high as 99.5%, outperforming conventional tools like GATK and SAMtools across various sequencing platforms, including Illumina, PacBio HiFi, and Oxford Nanopore.12

Specialized variations of these models have emerged to address specific clinical needs. DeepTrio, an extension of DeepVariant, incorporates familial context by jointly analyzing sequencing data from child-parent trios.12 This allows for a more accurate identification of de novo mutations by weighing the probability of sequencing errors against inherited patterns.12 Meanwhile, tools like DNAscope from Sentieon combine the efficiency of classical HaplotypeCaller algorithms with machine learning refinement, offering a high-accuracy, low-computational-cost alternative to pure deep learning models.12



Figure 1. Integrated AI-genomics workflow from data generation to clinical application. High-throughput sequencing and multi-omics data are processed using AI models, including CNNs, transformers, and generative AI.

7 Functional Annotation And Pathogenicity Prediction

Beyond mere identification, the functional annotation of variants is critical for clinical interpretation. AI models now integrate a multitude of features, including evolutionary conservation, regulatory annotations, and protein structural context, to predict whether a variant is benign or pathogenic.14 More recent deep learning approaches have demonstrated that variant effect prediction can be substantially improved by incorporating near-atomic protein structure predictions from models like AlphaFold2.2

In the realm of functional genomics, AI identifies regulatory elements and transcription factor binding sites with high precision.7 These models can accommodate longer genomic inputs, allowing them to capture the influence of distal enhancers on gene expression.7 This is particularly relevant for interpreting the non-coding regions of the genome, which were previously considered "dark matter" but are now known to harbor many disease-associated variations.7

8 Multi Omics Integration A Holistic View Of Biological Systems

Modern biological research increasingly relies on the simultaneous measurement of multiple molecular layers genomics, transcriptomics, proteomics, metabolomics, and epigenomics to construct a comprehensive picture of cellular physiology.14 Integrating these heterogeneous, high-dimensional datasets presents formidable challenges, including differences in data scale, noise characteristics, and the underlying biological mechanisms.8

Strategies For Modal Fusion

AI methods, particularly deep learning architectures designed for multi-modal data fusion, have emerged as the standard for integrating these datasets.14 Autoencoders and Variational Autoencoders (VAEs) are used extensively for unsupervised multi-omics integration, learning shared latent representations that capture biological variations common across layers while filtering out modality-specific noise.14 Graph-based methods represent multi-omics data as biological networks, incorporating gene regulatory and protein-protein interaction structures to improve disease subtype classification.14

This integrative approach is the linchpin for "Truly Predictive Therapeutics".9 Industry pioneers like SOPHiA GENETICS and Tempus are leveraging multi-modal AI to tailor patient treatments, moving beyond the single-gene diagnostic paradigm.9 For instance, combining genomic alterations with transcriptomic expression patterns and digital pathology images provides an unparalleled view of the tumor microenvironment, allowing for the

identification of patients who are most likely to benefit from immunotherapy.21

9 Ai In Clinical Genetics From Diagnosis To Predictive Medicine

In the clinical setting, AI is evolving from a purely interpretative tool to a predictive and preventive partner.24 Current applications focus on streamlining the diagnostic pipeline for rare and complex diseases, while future trajectories aim for early intervention and personalized prevention.17

Diagnostic Acceleration And Clinical Phenotyping

One of the most impactful uses of AI in clinical genetics lies in variant classification according to international standards (e.g., ACMG/AMP).24 AI algorithms can prioritize candidate pathogenic variants by integrating facial image analysis, clinical notes from EHRs, and genetic sequences.17 For example, the GestaltMML system uses multi-modal transformers to analyze patient photos and clinical metadata, significantly improving the accuracy of identifying syndromic features and their underlying genetic causes.4

In neonatal and pediatric settings, where time is of the essence, AI-driven pipelines can reduce the time to diagnosis from weeks to hours.25 Generative models like GPT-4 and Gemini have demonstrated the ability to suggest tentative molecular diagnoses for autoinflammatory and neurogenetic disorders based on textual summaries of EHRs.4 These tools act as decision support systems, allowing clinicians to navigate vast amounts of scientific literature to stay updated on rare disease research and emerging therapies.4

The Emergence Of Digital Twins And Personalized Prognosis

Looking forward, the concept of the "Personalized Digital Twin" is poised to transform clinical management.9 A digital twin is a virtual replica of a patient created by fusing multi-omics data with longitudinal health records.9 These models can simulate how a patient will respond to a specific drug or how a disease will progress over time, effectively allowing for "in-silico" clinical trials before a treatment is ever administered.9 This approach is already showing promise in oncology, where AI correlates morphological features with clinical outcomes to facilitate risk stratification and predict cancer recurrence.24

10 Oncology And The Real Time Surveillance Paradigm

Cancer management is undergoing a revolution driven by AI-enhanced liquid biopsies and real-time genomic monitoring.26 Traditionally, tissue biopsies were the gold standard but were limited by invasiveness and sampling bias.26 AI-powered liquid biopsies offer a non-invasive alternative by analyzing circulating tumor DNA (ctDNA) and other biomarkers from blood samples.15

Liquid Biopsy And Minimal Residual Disease Mrd

AI models excel at detecting the faint signal of tumor-derived mutations against the background of healthy DNA.15 Techniques like fragmentomics and DNA methylation analysis, combined with supervised machine learning, have enabled the detection of early-stage cancers with high specificity.15 The K-DETEK model, for instance, achieved 78.1% sensitivity and 99.8% specificity in multi-cancer detection, significantly outperforming single-omic tests.22

Real-time monitoring of Minimal Residual Disease (MRD) is perhaps the most critical application of this technology.22 By tracking ctDNA mutation dynamics during and after treatment, AI can detect emerging resistance mutations such as those in EGFR or KRAS weeks or even months before clinical relapse is visible on a scan.27 This provides a narrow but vital window for clinicians to escalate or switch therapies, potentially extending progression-free survival.22

Precision Diagnostics In Challenging Scenarios

AI is also bridging the gap in the diagnosis of Cancers of Unknown Primary (CUP). By integrating genomic and transcriptomic profiling with longitudinal monitoring, AI platforms have achieved an 87.7% accuracy rate in predicting the tissue-of-origin for these challenging cases.22 This capability ensures that patients with metastatic disease can receive targeted therapies tailored to the primary tumor's biology, even when the primary site remains hidden.22

11 Genomic Surveillance And Pathogen Tracking In Global Health

The lessons learned during the COVID-19 pandemic have solidified the role of AI-enhanced genomic surveillance as a cornerstone of global biosecurity.28 Genomic surveillance involves the constant monitoring of pathogens to analyze their genetic similarities

and predict transmission chains and antimicrobial resistance (AMR).28

Real Time Outbreak Detection And Analysis

During the SARS-CoV-2 pandemic, platforms like GISAID and Nextstrain enabled the real-time tracking of variant evolution and transmission hotspots.28 AI integration has further optimized this process; the EDS-HAT tool leverages AI to automate the analysis of EHRs alongside whole-genome sequencing (WGS) data.23 In clinical trials involving 172 outbreaks, this AI-driven approach identified 37 transmission routes missed by manual review, including procedures and provider-mediated routes.23 The algorithm achieved an overall sensitivity of 91.7% in identifying epidemiological links.23

The shift toward decentralization is another key trend. Open-source software like MARTi now allows for real-time metagenomic analysis in the field using standard laptops.30 This technology enables "AirSeq" or "WaterSeq" surveillance, where environmental samples are continuously monitored for pathogen threats.30 In an agricultural setting, this could mean a literal "box in a field" that alerts a farmer to the presence of a specific crop pathogen in real time.30

One Health And Pandemic Preparedness

The WHO Global Genomic Surveillance Strategy (2022–2032) aims to unify these efforts into a One Health framework that bridges human, animal, and environmental health.29 AI-driven "agnostic" or metagenomic sequencing is advocated as the most promising strategy for detecting "Disease X" a novel, unknown pathogen with pandemic potential.31 By monitoring cross-species spillover events in real time, AI can provide the early warning signals needed to prevent a local outbreak from becoming a global catastrophe.31

12 The Autonomous Lab Self Driving Research Ecosystems

The ultimate vision of AI in genomics is the "Self-Driving Laboratory" (SDL), where machines perform the entire scientific method with minimal human intervention.1 These labs represent a shift from mechanical automation to cognitive automation, where AI not only executes experiments but also generates hypotheses and interprets results.1

13 Data Privacy And The Ethics Of Early Life Settings

14 The Dbtl Cycle And Robotic Scientists

An autonomous lab operates on the Design-Build-Test-Learn (DBTL) cycle.1 A coordinating AI agent oversees three specialized agents: the "generator" designs virtual organisms or genomic sequences; the "builder" uses robotic arms and DNA synthesis tools to construct them; and the "analyzer" processes the experimental data (from PCR, plate readers, or sequencers) to refine the model.1

15 These Systems Offer Several Advantages

Efficiency: SDLs run 24/7, reducing the time from hit identification to lead optimization in drug discovery from months to days.33

Reproducibility: By automating every step, SDLs can address the "reproducibility crisis," where nearly 70% of scientists struggle to replicate others' findings.33

Exploration of Search Spaces: AI can search vast chemical and genetic libraries that would be impossible for human scientists to navigate manually.32

However, the question of accountability remains paramount. If an AI-driven lab produces a flawed or harmful conclusion, the responsibility must still lie with human supervisors.1 Current frameworks emphasize that SDLs are "force multipliers" rather than replacements, allowing scientists to focus on high-level creativity and ethical oversight.1

16 Ethical Regulatory And Technical Challenges

The rapid adoption of AI in genomics introduces complex challenges that require proactive intervention and robust governance.

17 Algorithmic Bias And Data Equity

The most pervasive issue is the risk of bias in AI algorithms.35 Because models are typically trained on available data, which is heavily skewed toward individuals of European ancestry, they may not generalize well to racially and ethnically diverse populations.36 This can lead to disparities in medical decisions that disproportionately affect marginalized groups.35 For example, a model trained on cost as a proxy for illness was found to exhibit racial bias by failing to identify the health needs of Black patients accurately.36 Addressing this requires a multi-faceted approach: enriching datasets with diverse populations, implementing bias-aware training methodologies

Table 1. Table 1

Paradigm	Architecture Focus	Primary Genomic Applications	Strengths	Limitations
Supervised Learning	CNNs, DNNs	Variant calling, disease classification, protein structure	High accuracy, well-defined benchmarks	Reliance on large labeled datasets, risk of overfitting
Unsupervised Learning	Autoencoders, K-means	Cell state discovery, dimensionality reduction, anomaly detection	No labels required, finds hidden structures	Risk of learning spurious patterns, hard to validate
Reinforcement Learning	Deep Q-Networks	CRISPR optimization, drug design, lab automation	Adaptive, optimizes for long-term rewards	Computationally expensive, requires simulation environment
Generative AI	Transformers, GANs	Sequence design, protein synthesis, data augmentation	Creates novel functional data, overcomes data sparsity	Ensuring biological viability of generated outputs

Table 2. Table 2

Tool/Platform	Developer	Core Technology	Primary Function	Key Performance Metric
DeepVariant	Google Health	CNN (Inception-v3)	Variant Calling	SNV F1 Score: 99.5% 14
AlphaFold2	DeepMind	Evoformer + SE(3)	Protein Structure Prediction	Median 0.96 Å error 2
DNAscope	Sentieon	ML-Augmented GATK	Efficient Variant Detection	Low memory overhead, high speed 12
GestaltMML	Freenome/Tempus	Multi-modal Transformer	Syndromic Diagnosis	Improved identification of causal variants 4
SPOT-MAS	Gene Solutions	Supervised ML	Liquid Biopsy (10+ cancers)	High TOO accuracy (84%) 22
EDS-HAT	Healthcare AI	EHR-Genomic Fusion	Outbreak Investigation	91.7% sensitivity in transmission links 23
CRISPR-GPT	Research Consortium	LLM / Agentic AI	Gene Editing Design	Automated guide RNA optimization 4

like adversarial debiasing, and conducting ongoing fairness audits.35

18 The Black Box Problem And Transparency

Many deep learning models are "black boxes" their decision-making processes are not transparent to human users.36 In clinical genomics, understanding the "why" behind a prediction is essential for informed decision-making and patient trust.25 Regulatory frameworks like the EU AI Act categorize AI systems based on risk, placing high transparency and explainability requirements on medical tools.17 Companies are responding by developing explainable AI (XAI) tools like eVai, which provide transparent justifications for variant classification.17

Genomic data is uniquely personal and identifiable, raising profound privacy concerns.25 In prenatal and pediatric settings, the stakes are even higher, as AI decisions can impact a child's entire future.25 Concerns about genetic discrimination and "misguided trust" in machines necessitate that humans remain in full control of critical medical decisions.25 Furthermore, as AI permeates healthcare, clear policies for data governance, safeguarding, and accessibility must be established to ensure patient autonomy and informed consent.17

19 Future Perspectives And 2035 Roadmap

As we look toward 2035, the convergence of AI and genomics will be shaped by several emerging trends. (Figure 2)

AI Sovereignty and Localized Models: Countries are increasingly seeking to build their own LLMs or run existing models on local hardware to ensure data security and political independence.39

Quantum Machine Learning: The potential for quantum hardware to model molecular dynamics and complex genetic interactions at currently impossible



Figure 2. Emerging AI-driven autonomous genomics ecosystem.

scales may eventually unlock the next level of genomic resolution.14

Digital CDx and Multimodal Signatures: Future clinical trials will likely randomize patients based on AI-derived multimodal signatures integrating genomics, imaging, and EHR data rather than single-gene biomarkers.9

Real-Time Global Surveillance Ecosystems: By 2032, the integration of real-time metagenomics and AI will enable a global "Early Warning System" for pathogens, potentially ending the era of pandemics through rapid detection and localized response.29

20 Conclusion

The marriage of AI and genomics is no longer a distant promise but a transformative reality that is already improving diagnostic accuracy and drug discovery. To ensure this technology reaches its full potential, the research community must prioritize:

Dataset Diversity: Actively curating diverse genomic and phenotypic data to mitigate bias.35

Algorithmic Transparency: Designing interpretable models that can be audited by clinicians.17

Ethical Oversight: Establishing clear lines of accountability for autonomous systems and protecting the privacy of vulnerable populations.25

Infrastructure Standardization: Creating interoperable AI ecosystems that can scale these innovations across regions and healthcare sectors.9

By viewing AI as a collaborative partner rather than a replacement, we can transition clinical genetics from a field that primarily diagnoses disease to one that actively prevents and cures it.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] R&D World. (n.d.). *The self-driving lab: A new roadmap for automation in synthetic biology*. Retrieved from https://www.rdworldonline.com/the-self-driving-lab-a-new-roadmap-for-automation-in-synthetic-biology/

[2] Oxford Academic. (n.d.). *Artificial intelligence in bioinformatics: A survey*. Retrieved from https://academic.oup.com/bib/article/26/6/bbaf576/8315885

[3] ResearchGate. (n.d.). *A systematic review on the generative AI applications in human medical genetics*. Retrieved from https://www.researchgate.net/publication/399917270_A_systematic_review_on_the_generative_AI_applications_in_human_medical_genetics

[4] National Center for Biotechnology Information. (n.d.). *A systematic review on the generative AI applications in*

human medical genomics. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12863965/

[5] CABI Digital Library. (n.d.). *Artificial intelligence in functional genomics of plants*. Retrieved from https://www.cabidigitallibrary.org/doi/10.1079/9781800628649.0002

[6] National Center for Biotechnology Information. (n.d.). *Integrating artificial intelligence in next-generation sequencing: Advances, challenges, and future directions*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12191491/

[7] MDPI. (n.d.). *Advances in artificial intelligence models and generative algorithms in genomics research*. Retrieved from https://www.mdpi.com/1422-0067/26/22/10925

[8] National Center for Biotechnology Information. (n.d.). *Artificial intelligence drives advances in multi-omics analysis and precision medicine*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12937605/

[9] BC-LA. (n.d.). *Transforming life sciences through AI-driven multi-omics integration*. Retrieved from https://www.bc-la.org/consulting-2/beyond-expectations%3A-transforming-life-sciences-through-ai-driven-multi-omics-integration-

[10] National Center for Biotechnology Information. (n.d.). *Revolutionizing personalized medicine using multi-omics*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11673561/

[11] Quanticate. (n.d.). *Multi-omics and its application in personalised medicine*. Retrieved from https://www.quanticate.com/blog/multi-omics-personalised-medical-studies

[12] ResearchGate. (n.d.). *Artificial intelligence in variant calling: A review*. Retrieved from https://www.researchgate.net/publication/391567148_Artificial_intelligence_in_variant_calling_a_review

[13] National Center for Biotechnology Information. (n.d.). *Artificial intelligence in variant calling*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12055765/

[14] ResearchGate. (n.d.). *Artificial intelligence for scientific discovery and genomics*. Retrieved from https://www.researchgate.net/publication/402599190_Artificial_Intelligence_for_Scientific_Discovery_and_Genomics

[15] MDPI. (n.d.). *Artificial intelligence-enhanced liquid biopsy in cancer detection*. Retrieved from https://www.mdpi.com/2072-6694/17/19/3165

[16] arXiv. (n.d.). *Generative AI applications in human genomics*. Retrieved from https://arxiv.org/html/2508.20275v1

[17] enGenome. (n.d.). *Artificial intelligence regulation in clinical genomics*. Retrieved from https://www.engenome.com/news/AI-regulation/

[18] National Center for Biotechnology Information. (n.d.). *Artificial intelligence in genetics*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10856672/

[19] DevOpsSchool. (n.d.). *Top AI genetic analysis tools in 2026*. Retrieved from https://www.devopsschool.com/blog/top-10-ai-genetic-analysis-tools-in-2025-features-pros-cons-comparison/

[20] Riveraxe. (n.d.). *AI vs traditional bioinformatics methods*. Retrieved from https://riveraxe.com/ai-vs-traditional-methods-in-bioinformatics-data-analysis/

[21] Precision for Medicine. (n.d.). *AI and multi-omics in translational research*. Retrieved from https://www.precisionformedicine.com/blog/developing-a-comprehensive-strategy-for-implementing-ai-multi-omics

[22] Gene Solutions. (n.d.). *AI-powered liquid biopsy and multi-omics*. Retrieved from https://genesolutions.com/news/bridging-genomic-insights-ai-powered-liquid-biopsy

[23] National Center for Biotechnology Information. (n.d.). *AI in genomic surveillance for outbreak investigations*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12926331/

[24] National Center for Biotechnology Information. (n.d.). *Applications of AI in clinical genetics*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12860534/

[25] National Center for Biotechnology Information. (n.d.). *Ethics of AI in genomic medicine*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10857992/

[26] PubMed. (n.d.). *Liquid biopsy in cancer diagnosis*. Retrieved from https://pubmed.ncbi.nlm.nih.gov/41602544/

[27] National Center for Biotechnology Information. (n.d.). *AI-enhanced liquid biopsy monitoring*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12688787/

[28] Public Health AI Handbook. (n.d.). *AI in genomic surveillance*. Retrieved from https://publichealthaihandbook.com/applications/genomics.html

[29] World Health Organization. (n.d.). *WHO genomic surveillance strategy*. Retrieved from https://www.who.int/initiatives/genomic-surveillance-strategy

[30] News-Medical. (n.d.). *Real-time pathogen surveillance systems*. Retrieved from https://www.news-medical.net/news/20251028/New-software-enables-real-time-pathogen-surveillance.aspx

[31] Frontiers. (2024). *Real-time genomic surveillance*. Retrieved from https://www.frontiersin.org/articles/10.3389/fsci.2024.1298248/full

[32] National Center for Biotechnology Information. (n.d.). *Autonomous self-driving laboratories*. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12368842/

[33] Athens Science Observer. (2025). *Rise of self-driving labs*. Retrieved from https://athensscienceobserver.com/2025/06/18/laboratories-running-by-themselves

[34] Drug Target Review. (n.d.). *Self-driving labs in drug development*. Retrieved from https://www.drugtargetreview.com/how-self-driving-labs

[35] Journal of Young Investigators. (2026). *Bias in medical AI*. Retrieved from https://www.jyi.org/2026-january-1/2026/1/8/bias-in-medical-ai

[36] Centers for Disease Control and Prevention. (2024). *Health equity and AI in medicine*. Retrieved from https://www.cdc.gov/pcd/issues/2024/24_0245.htm

[37] Public Policy Projects. (n.d.). *AI in genomics: Opportunities and challenges*. Retrieved from https://publicpolicyprojects.com/the-role-of-ai-in-genomics

[38] Sano Genetics. (n.d.). *Ethical considerations of AI in precision medicine*. Retrieved from https://sanogenetics.com/resources/blog/challenges-and-ethical-considerations

[39] Stanford University Human-Centered Artificial Intelligence. (n.d.). *AI future predictions*. Retrieved from https://hai.stanford.edu/news/stanford-ai-experts-predict

Citation

Babajan Banaganapalli (2026). AI-Driven Genomics Architectures Applications And The Transition To Self Driving Biomedical Systems. Journal of Advanced Medicine (JAM), Vol. 2, No. 1, 2026, 29-37.